Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05539157
Other study ID # 2021-JCXH-211-001
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date October 18, 2022
Est. completion date May 2024

Study information

Verified date April 2023
Source Immorna Biotherapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors


Description:

The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase 1a and Phase 1b. Phase 1a has 3 stages, Single administration stage, Multiple administration stage and Visceral stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1
Est. completion date May 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: All of the following conditions should be met at screening: - Male or female patients 18-75 - Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology - Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist - Patients with at least one non-injected measurable tumor lesion per RECIST v1.1 - Patients with lesions suitable for intratumoral injection (the lesion length is at least 10 mm and not exceeding 80 mm) - Patients enrolled in the single and multiple administration stages of Phase 1a must agree to provide pre- and post-treatment tumor biopsy tissues - Patients must have adequate organ and marrow functions - Patients with treated brain metastases are eligible if meeting protocol's requirement - Patients must be = 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy Exclusion Criteria: Patients who meet any of the following criteria will be excluded from study entry: - Patients who have received prior IL-12 either alone or as part of a treatment regimen - Patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) - Patients requiring therapeutic doses of anticoagulation - Patients with tumors that impinge on major airways, blood vessels, or nerve bundles - Patients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications - Patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment - Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment - Patient with history of solid organ or allogenic bone marrow transplantation

Study Design


Intervention

Drug:
JCXH-211
JCXH-211 administered once every 28 days

Locations

Country Name City State
United States The University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Immorna Biotherapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity Dose limiting toxicity, evaluated in the single administration stage of Phase 1a, which will be used to determine the MTD and to determine dose escalation Day 1 to Day 29
Primary Incidence of adverse events (Safety and Tolerability) Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs) From consent to 30 days after the last dose of study drug
Secondary Objective response rate (ORR) Objective response rate is defined as the proportion of patients that achieve a complete response (CR) or partial response (PR) during the study participation. Up to 12 months
Secondary Duration of response (DOR) Duration of response is defined as the time from the first assessment of tumor as CR or PR to the first assessment as progressive disease or death from any cause. Up to 12 months following first reported response
Secondary Time to response (TTR) Time to response is defined as the time from Day 1 until the first documentation of objective response (CR or PR). Up to 12 months from the start of study therapy
Secondary Disease control rate (DCR) Disease control rate is defined as the proportion of patients with CR or PR or stable disease (SD) with the DOR = 12 weeks observed from Day 1 to disease progression. Up to 12 months
Secondary Progression-free survival (PFS) Progression-free survival is defined as the time from Day 1 to disease progression or death from any cause, whichever occurs earlier. Up to 12 months
Secondary Overall survival (OS) Overall survival is defined as the time from Day 1 until death due to any cause. Up to 24 months
See also
  Status Clinical Trial Phase
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT01648764 - A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05141474 - Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors Early Phase 1
Active, not recruiting NCT02999750 - EXtendedAnalysis for Cancer Treatment N/A
Completed NCT01457118 - An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Phase 2
Recruiting NCT04571892 - A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05468359 - Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Phase 1/Phase 2
Recruiting NCT04168528 - Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT Phase 1/Phase 2
Recruiting NCT04145622 - Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT06057038 - A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors Phase 1
Completed NCT02844400 - Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT00452413 - A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer Phase 1/Phase 2
Completed NCT03553108 - A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. Phase 1
Recruiting NCT06391775 - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy Phase 1/Phase 2
Recruiting NCT04076137 - Targeted T-cell Therapy in Solid Tumors Early Phase 1
Terminated NCT03192345 - A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02754141 - An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab Phase 1/Phase 2